The results of the national talks are released. The full analysis of key products involves Hengrui, Rongchang, and Geli Pharmaceuticals, etc.

1.

From the perspective of the rate of decrease, the average price reduction of 67 drugs entered through negotiations this time was 61.

As an important catalyst for increasing the volume of drugs, medical insurance negotiations are an important link between the research and development and commercialization of innovative drugs

2.

Chart: The number of newly-added products of the national medical insurance negotiation enterprises

1.

For Hengrui Medicine, a total of four products have been successfully included in the medical insurance catalog

Remazolam tosylate is a short-acting GABAa receptor agonist with fast onset and rapid failure.

Fluzoparib capsules are small molecule PARP inhibitors, which can inhibit the DNA repair process in BRCA1/2 dysfunctional cells, induce cell cycle arrest, and then inhibit tumor cell proliferation

Hetropopaethanolamine is an orally absorbed small molecule non-peptide thrombopoietin receptor (TPOR) agonist, which activates TPOR-dependent STAT and TPOR by selectively binding to the transmembrane region of the thrombopoietin receptor The MAPK signal transduction pathway stimulates the proliferation and differentiation of megakaryocytes to produce platelets to increase platelets

Azilsartan is an angiotensin II receptor antagonist (ARB) class of antihypertensive drugs.

2.

Rongchang Biotech can be regarded as the big winner of this medical insurance negotiation.

Vedicitumumab for injection is an antibody-conjugated drug (ADC), approved for marketing in June 2021, for HER2 overexpression locally advanced or metastatic gastric cancer that has received at least two systemic chemotherapy

Tacitazep for injection is a TACI-Fc fusion protein drug that prevents B lymphocyte stimulating factor (BLyS) and proliferation inducing ligand (APRIL) from binding to BAFF-R, BCMA and TACI receptors expressed on the surface of B cells , Inhibit BLyS and APRIL signal transduction, and inhibit the development and survival of mature B cells and plasma cells

3.
Kerry Pharmaceuticals

Following the failure of medical insurance in 2019 and 2020, Danoprevir sodium tablets of Kerry Pharmaceuticals were finally included in medical insurance.
Although the medical insurance was late, it was not absent after all
.
Regarding the inclusion of the two types of medical insurance, the company is full of confidence in the future development.
On December 3, it repurchased 689,000 shares on the Hong Kong Stock Exchange, and the company's stock price rose 11% intraday
.

Danorevir sodium tablets are already an old friend of hepatitis C patients.
Danorevir sodium tablets were launched in 2018.
It is the first domestically-developed DAA class 1 new drug, breaking Gilead, AbbVie, Bristol-Myers Squibb and other U.
S.
pharmaceutical companies to C Monopoly of the hepatitis treatment drug market
.
Lavidavir hydrochloride tablets is an NS5A inhibitor, launched in July 2020.
The indications are danoprevir sodium tablets and ribavirin fortified with ritonavir for the treatment of newly diagnosed gene 1b Non-cirrhotic adult patients with chronic hepatitis C virus infection
.

4.
Brief analysis of other key varieties

Iris-Vometinib mesylate is the third-generation EGFR-TKI, which was approved for marketing in March 2021, officially opening a fair competition with osimertinib and ametinib
.

Haisco—Cyclopofol is a GABAA receptor agonist and an anesthetic sedative.
Compared with propofol, cyclopofol has a stronger affinity for GABAA receptors, and its therapeutic index is approximately 2.
4 times that of propofol.
It is included in medical insurance It has a positive effect on entering the hospital and increasing the volume of products
.

Betta Pharmaceuticals-Ensatinib is an ALK inhibitor, used for the treatment of ALK-positive non-small cell lung cancer.
With Ensatinib included in the medical insurance, Betta Pharmaceuticals finally got rid of icotinib.
"The problem of walking, in addition, relying on the mature sales team built by Icotinib, the expected volume of Ensatinib is high
.

Nuocheng Jianhua——Obutinib is a BTK inhibitor used for the treatment of mantle cell lymphoma and other treatments.
Considering that both Zebutinib and Ibrutinib have been included in the medical insurance, abrutinib is included in the medical insurance this time It is very important for the product volume
.
At the same time, as Nuocheng Jianhua's first commercialized drug, the commercialization success of Obutinib has a demonstrative effect
.

Hisun Pharmaceuticals-Haibo Mebu is the first oral intestinal cholesterol absorption inhibitor in China and the second in the world
.
It provides a new medication choice for patients who cannot tolerate high-dose statins .
Medical insurance is expected to give the drug the wings to take off, but the high dependence on the sales of statin drugs may still be the bottleneck of the increase in the volume of ezetimibe and hypermebe
.

3.
Summary

Although the results of this year's medical insurance negotiations have been announced, the prices of most drugs have not been announced
.
Taking into account that the new version of the medical insurance catalog will be implemented on January 1, 2022, the extent of drug price reductions can be further seen through the flow of drugs at that time
.
Regarding medical insurance negotiations, it cannot be simply interpreted as a favorable policy of "quantity for price".
After some drugs are included in medical insurance, although sales have increased rapidly, due to the sharp decline in prices, sales eventually declined instead of increasing
.
In addition, due to the inclusion of competing products in medical insurance, fierce competition may weaken the advantages of medical insurance
.
In the final analysis, the core of medical insurance lies in the trade-off relationship between volume and price, which deserves special attention
.